ATE285247T1 - Krebstherapie mit lymphotoxin - Google Patents

Krebstherapie mit lymphotoxin

Info

Publication number
ATE285247T1
ATE285247T1 AT95924715T AT95924715T ATE285247T1 AT E285247 T1 ATE285247 T1 AT E285247T1 AT 95924715 T AT95924715 T AT 95924715T AT 95924715 T AT95924715 T AT 95924715T AT E285247 T1 ATE285247 T1 AT E285247T1
Authority
AT
Austria
Prior art keywords
lymphotoxin
cancer therapy
cancer
vivo
therapy
Prior art date
Application number
AT95924715T
Other languages
English (en)
Inventor
David V Goeddel
Grace H W Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE285247T1 publication Critical patent/ATE285247T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95924715T 1994-07-01 1995-06-26 Krebstherapie mit lymphotoxin ATE285247T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26970494A 1994-07-01 1994-07-01
US08/418,314 US5747023A (en) 1994-07-01 1995-04-07 Cancer therapy using lymphotoxin
PCT/US1995/008085 WO1996001121A1 (en) 1994-07-01 1995-06-26 Cancer therapy using lymphotoxin

Publications (1)

Publication Number Publication Date
ATE285247T1 true ATE285247T1 (de) 2005-01-15

Family

ID=26953844

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95924715T ATE285247T1 (de) 1994-07-01 1995-06-26 Krebstherapie mit lymphotoxin

Country Status (10)

Country Link
US (1) US5747023A (de)
EP (1) EP0768889B1 (de)
JP (1) JPH10502371A (de)
AT (1) ATE285247T1 (de)
AU (1) AU712197B2 (de)
CA (1) CA2191696A1 (de)
DE (1) DE69533873T2 (de)
IL (1) IL114382A (de)
MX (1) MX9606559A (de)
WO (1) WO1996001121A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
ZA964382B (en) * 1995-06-06 1997-12-01 Genentech Inc Lymphotoxin and thrombopoietin for use in the treatment of cancer.
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EP0832653A1 (de) * 1996-09-20 1998-04-01 Max-Delbrück-Centrum Für Molekulare Medizin Verwenddung von Cytokinen und cytotoxischen Substanzen in einem neuen Verfahren zur Tumorbehandlung
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DK1051187T3 (da) * 1998-01-30 2004-03-08 Univ New York Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen
GB9808796D0 (en) * 1998-04-24 1998-06-24 Rowett Research Services Limit Antithrombotic agents
EP2084188A2 (de) 2006-10-12 2009-08-05 Genentech, Inc. Antikörper gegen lymphotoxin-alpha
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
WO2009062344A1 (en) * 2007-11-16 2009-05-22 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Use of lymphotoxin for sensitizing tumor cells to chemotherapeutic drugs
US9958456B2 (en) 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
EP3738651A1 (de) * 2019-05-16 2020-11-18 Klinikum rechts der Isar der Technischen Universität München Lymphotoxin alpha zur verwendung bei der behandlung von myeloischer leukämie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405601A (en) * 1981-05-21 1983-09-20 Cancer Research Center Extraction and purification of biologically active lymphokines
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4959457A (en) * 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
NZ212207A (en) * 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
GR851626B (de) * 1984-07-05 1985-11-26 Genentech Inc
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
DE3613167A1 (de) * 1986-04-18 1987-10-29 Basf Ag Verwendung von tnf zur herstellung von arzneimitteln
JPS63245692A (ja) * 1987-04-01 1988-10-12 Kanegafuchi Chem Ind Co Ltd ヒト・リンホトキシンまたはその組成物
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
AU3578189A (en) * 1988-04-27 1989-11-24 Immunomedics Inc. Improved radiotherapy

Also Published As

Publication number Publication date
AU712197B2 (en) 1999-10-28
IL114382A0 (en) 1995-10-31
EP0768889A1 (de) 1997-04-23
US5747023A (en) 1998-05-05
DE69533873D1 (de) 2005-01-27
CA2191696A1 (en) 1996-01-18
MX9606559A (es) 1997-03-29
IL114382A (en) 2005-12-18
JPH10502371A (ja) 1998-03-03
DE69533873T2 (de) 2005-12-29
EP0768889B1 (de) 2004-12-22
AU2911595A (en) 1996-01-25
WO1996001121A1 (en) 1996-01-18

Similar Documents

Publication Publication Date Title
NO20054988D0 (no) Preparater og metoder for behandling av cancer
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
DE69533873D1 (de) Krebstherapie mit lymphotoxin
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
NZ337493A (en) Use of a reovirus for treating Ras-mediated neoplasms
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
ZA200005475B (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with anglogenesis inhibitor.
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
BG103832A (en) Leptin as tumour cells proliferation inhibitor
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
IS5570A (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
TR199903074T2 (xx) Kanser tedavisinde HMG CoA ve farnesil transfer �nleyicileri.
PT980205E (pt) Utilizacao da combinacao de celulas tall-104 com adriamicina ou cisplatina na terapia de tumores malignos
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
ATE78164T1 (de) Verwendung von metalloporphyrin zur umkehr des toxischen effekts der tumortherapie.
DK0938900T3 (da) Midler til forebyggelse/behandling af stomatitis
NZ510445A (en) A method for intrahepatic administration of methoxymorpholino doxorubicin (MMDX) to achieve a high concentration at a hepatic tumour site
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
NZ506005A (en) Recombinant proteins derived from hgf and msp
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0768889

Country of ref document: EP